Streetbeat News

Analyst Ratings

UPS

Barclays analyst Brandon Oglenski maintains an Equal-Weight rating on United Parcel Service (UPS) but lowers the price target from $180 to $175.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 10:09 am

RLJ

Barclays analyst Anthony Powell has maintained an Equal-Weight rating on RLJ Lodging (NYSE:RLJ) and lowered the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 10:07 am

PNW

Barclays analyst Eric Beaumont has maintained an 'Overweight' rating on Pinnacle West Capital (NYSE:PNW) but lowered the price target from $81 to $77.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 10:05 am

NXT

Barclays analyst Christine Cho maintains an Overweight rating on NEXTracker (NASDAQ:NXT) but lowers the price target from $52 to $50.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 10:03 am

AMZN

Needham analyst Laura Martin has reiterated a 'Buy' rating on Amazon.com (NASDAQ:AMZN) and maintained a price target of $160.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 10:02 am

SHO

Barclays analyst Anthony Powell maintains an Underweight rating on Sunstone Hotel Invts (NYSE:SHO) and has lowered the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 10:02 am

HST

Barclays analyst Anthony Powell maintains an Overweight rating on Host Hotels & Resorts (NASDAQ:HST) but lowers the price target from $22 to $21.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 10:00 am

TMO

Bernstein analyst Eve Burstein has initiated coverage on Thermo Fisher Scientific (NYSE:TMO) with an Outperform rating and a price target of $603.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 9:59 am

ARRY

Barclays analyst Christine Cho maintains an Overweight rating on Array Technologies (NASDAQ:ARRY) and raises the price target from $28 to $30.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 9:57 am

IRWD

JMP Securities analyst Jason Butler has initiated coverage on Ironwood Pharmaceuticals with a Market Outperform rating and a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 9:55 am